Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | UBE2N | P61088 | 1/20 | 0.81 |
| ▸ | HTR6 | P50406 | 11/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR1F | P30939 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576861 | 1.00 | KDM4E (0.81) | KDM4EUBE2NHTR6LMNASMN1; SMN2 | |
| SCHEMBL29694480 | 0.89 | KDM4E (1.00) | KDM4EUBE2NHTR6L3MBTL1CA2 | |
| SCHEMBL946372 | 0.89 | KDM4E (1.00) | KDM4EUBE2NHTR6L3MBTL1CA2 | |
| SCHEMBL946492 | 0.88 | KDM4E (0.77) | KDM4EUBE2NHTR6LMNASMN1; SMN2 | |
| SCHEMBL14735529 | 0.88 | KDM4E (0.77) | KDM4EUBE2NHTR6L3MBTL1CA2 | |
| SCHEMBL30542061 | 0.88 | KDM4E (0.77) | KDM4EUBE2NHTR6SMN1; SMN2L3MBTL1 | |
| SCHEMBL946340 | 0.88 | KDM4E (0.77) | KDM4EUBE2NHTR6SMN1; SMN2L3MBTL1 | |
| SCHEMBL8582890 | 0.86 | KDM4E (0.65) | KDM4EUBE2NHTR6LMNASMN1; SMN2 | |
| SCHEMBL30542068 | 0.86 | KDM4E (0.73) | KDM4EUBE2NHTR6L3MBTL1CA2 | |
| SCHEMBL14735377 | 0.86 | KDM4E (0.73) | KDM4EUBE2NHTR6L3MBTL1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693500-A | Quinolinone derivative containing sulfonyl substituted indolyl acylhydrazone structure on 3-position nitrogen atom, and preparation method and application thereof | 太原理工大学 | 2023-09-05 | — | — | CN | claimed |
| CN-116693503-A | Quinolinone derivative containing sulfonyl substituted indolyl acylhydrazone structure on 1-position nitrogen atom, and preparation method and application thereof | 太原理工大学 | 2023-09-05 | — | — | CN | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230416239-A1 | COMPOUNDS AND METHODS FOR TREATING A CYTOKINE-MEDIATED DISEASE | CONSERVATOIRE NAT DES ARTS ET METIERS (FR) | 2023-12-28 | — | — | US | disclosed |
| CN-117003737-A | Substituted imidazolyl phenyl ketone compound, derivative and pharmaceutical composition thereof | 苏州泽璟生物制药股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116693500-A | Quinolinone derivative containing sulfonyl substituted indolyl acylhydrazone structure on 3-position nitrogen atom, and preparation method and application thereof | 太原理工大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-116693503-A | Quinolinone derivative containing sulfonyl substituted indolyl acylhydrazone structure on 1-position nitrogen atom, and preparation method and application thereof | 太原理工大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-114751891-B | (2- (1H-indole-3-yl) -1H-imidazole-4-yl) phenyl ketone compound and application thereof | 广东晨康生物科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114805307-A | Indole compound for preparing coronavirus therapeutic drug | 南京雷正医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-5811439-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS | SENGA PHARMACEUTICAL LABORATORY INC. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0584222-B1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0780389-A1 | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | KDM4E 1179/4885UBE2N 3095/4885HTR6 4243/4885 |
| US-20230416239-A1 | COMPOUNDS AND METHODS FOR TREATING A CYTOKINE-MEDIATED DISEASE | IL2, IL15, IL5 | KDM4E 4819/4885UBE2N 3482/4885HTR6 2769/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KDM4E 1179/4885UBE2N 3095/4885HTR6 4243/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | KDM4E 1179/4885UBE2N 3095/4885HTR6 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.